Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Liabilities and Shareholders Equity (2016 - 2025)

Fennec Pharmaceuticals' Liabilities and Shareholders Equity history spans 15 years, with the latest figure at $70.6 million for Q4 2025.

  • For the quarter ending Q4 2025, Liabilities and Shareholders Equity rose 56.97% year-over-year to $70.6 million, compared with a TTM value of $211.1 million through Dec 2025, down 10.64%, and an annual FY2025 reading of $70.6 million, up 56.97% over the prior year.
  • Liabilities and Shareholders Equity for Q4 2025 was $70.6 million at Fennec Pharmaceuticals, up from $49.3 million in the prior quarter.
  • The five-year high for Liabilities and Shareholders Equity was $70.6 million in Q4 2025, with the low at $15.6 million in Q2 2022.
  • Average Liabilities and Shareholders Equity over 5 years is $37.3 million, with a median of $28.1 million recorded in 2021.
  • Year-over-year, Liabilities and Shareholders Equity plummeted 44.63% in 2022 and then skyrocketed 224.95% in 2024.
  • Tracing FENC's Liabilities and Shareholders Equity over 5 years: stood at $26.0 million in 2021, then grew by 3.56% to $26.9 million in 2022, then dropped by 0.28% to $26.9 million in 2023, then skyrocketed by 67.31% to $44.9 million in 2024, then soared by 56.97% to $70.6 million in 2025.
  • Per Business Quant, the three most recent readings for FENC's Liabilities and Shareholders Equity are $70.6 million (Q4 2025), $49.3 million (Q3 2025), and $44.9 million (Q2 2025).